<DOC>
	<DOCNO>NCT01771328</DOCNO>
	<brief_summary>The conventional glucocorticoid replacement therapy congenital adrenal hyperplasia ( CAH ) render cortisol level unphysiological , may cause symptom long-term complication . Glucocorticoid replacement technically feasible continuous subcutaneous hydrocortisone infusion ( CSHI ) , mimic normal diurnal cortisol rhythm . This method recently apply treat patient critical phase puberty . This clinical trial aim evaluate CSHI treatment patient CAH . The main objective determine effect CSHI metabolic parameter ( androstenedione 17-hydroxyprogesterone profile , testosterone , adrenocorticotropic hormone ( ACTH ) , cortisol , bone marker ) , determine require glucocorticoid dos . Secondary objective determine effect clinical status , body weight , blood pressure metabolic parameter , well subjective health status ( AddiQoL , SF36 ) .</brief_summary>
	<brief_title>Continuous Subcutaneous Hydrocortisone Infusion Congenital Adrenal Hyperplasia</brief_title>
	<detailed_description>CAH patient treat glucocorticoids mineralocorticoid . Ideally , glucocorticoid dos sufficient suppress elevate ACTH secretion , hence attenuate increase androgen level . Because , CAH patient use high steroid dos patient autoimmune adrenal insufficiency ( Addison 's disease ) therefore high risk develop glucocorticoid side effect . The natural glucocorticoid , hydrocortisone ( cortisol ) cortisone acetate , prefer childhood growth suppressive effect longer act synthetic glucocorticoid , prednisolone dexamethasone . There consensus type glucocorticoid dos use adult CAH patient . Glucocorticoids display typical diurnal variation , current therapy restore , lead over- undertreatment . Some CAH patient experience symptom may due unphysiological glucocorticoid replacement therapy . For select CAH patient poor response conventional replacement therapy , problematic side effect impaired growth , weight gain , metabolic syndrome , osteoporosis , continuous subcutaneous hydrocortisone infusion ( CSHI ) might become treatment option . CSHI treatment would also facilitate use small disposable pump develop insulin treatment . CSHI : Pharmacodynamics , Pharmacokinetics , safety Hydrocortisone identical cortisol ; pharmacodynamics depend mode delivery . A hydrocortisone solution safely apply three day insulin pump without major day-to-day variation . A daily dose 10 mg/m2 body surface area/day restore normal level saliva cortisol patient . Thus , possible mimic physiological diurnal cortisol variation see healthy subject . The study compare two glucocorticoid replacement modality randomise order within patient . Prior Baseline period dose adjustment pump treatment . Patients educate group , dose adjustment co-ordinated regular visit outpatient clinic/telephone consultation combine laboratory analysis . The patient assign participation number randomise two treatment sequence ( A-B B-A ) . Should need extra glucocorticoid dose occur ( intercurrent illness ) study , patient administer previous glucocorticoid replacement safety reason . Extra dos record patient diary . Treatment A current treatment , i.e . glucocorticoid mineralocorticoid replacement accord best clinical judgement . Treatment B CSHI initial standard dose 10mg/m2/24hrs . Body surface area calculate accord nomogram formula Du Bois Du Bois . After 7 day initiate pump therapy patient reassess blood dot ( 17-hydroxyprogesterone ) saliva cortisol saliva 17-hydroxyprogesterone measurement morning ( 0800-0900 ) evening ( 2300-2400 ) . Based result test dose change discretion investigator . The new test do within 7-10 day . When final dose establish 24h urine measurement , blood test morning ( 17-hydroxyprogesterone cortisol ) salivary sample full profile ( full profile Hrs . 0800 , 0930 , 1100 , 1230 , 1700 , 2100 , 2400 , 0300 ) , do enter study . The dose adjustment period unlimited take minimally 4 week ( aim obtain normal range level morning serum cortisol ( 160- 620 nmol/l ) , 3-4 time increase morning serum 17-hydroxyprogesterone ( 0,3-8,6 nmol/l female , 0,9-6,6 nmo/l male ) , midnight ( 24:00 ) saliva cortisol ( &lt; 2,8 nmol/l ) circadian pattern indicate figure 1 . Afterwards 4 week wash period start , wash period treatment modality take 2 month .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Adrenal Hyperplasia , Congenital</mesh_term>
	<mesh_term>Adrenogenital Syndrome</mesh_term>
	<mesh_term>Adrenocortical Hyperfunction</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Cortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Cortisone</mesh_term>
	<mesh_term>Epinephrine</mesh_term>
	<mesh_term>Racepinephrine</mesh_term>
	<mesh_term>Epinephryl borate</mesh_term>
	<criteria>verified saltwasting CAH simple virilize CAH , single prednisone , hydrocortisone therapy . In case concomitant endocrine/autoimmune diseases stable treatment study period . Patients diabetes mellitus insulin pump treatment include study cardiovascular disease , active malignant disease pregnancy , pharmacological treatment glucocorticoid drug interfere cortisol metabolism ( antiepileptic , rifampicin , St. Johns wart ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Adrenal Hyperplasia , Congenital</keyword>
</DOC>